[Infostock Daily= Reporter Park Sang-In] The dispute of botulinum strains, which was continued by Daewoong Pharmaceutical Co., Ltd. and Meditox for five years, is expected to be concluded this week.
The U.S. International Trade Commission(ITC) is scheduled to make a preliminary ruling on the dispute of botulinum strain between Meditox and Daewoong Pharmaceutical Co., Ltd. on the 6th. In January last year, Meditox filed an official complaint with the U.S. ITC on charges of violating business secrets, saying that Daewoong Pharmaceutical Co., Ltd. has stolen the toxin strains from the botulinum and technical documents containing the manufacturing process.
Botulinum strains are the raw materials for botulinum toxin, which is called `Botox’. Meditox has its own botulinum toxin formulation called `Meditoxin’ and Daewoong Pharmaceutical Co., Ltd. has its own botulinum toxin formulation called `Nabota’.
The ITC was scheduled to make a preliminary ruling early last month, but changed its schedule by receiving additional documents from Daewoong Pharmaceutical Co., Ltd..
Daewoong Pharmaceutical Company Co., Ltd. is reported to have submitted that Meditox violated the Pharmaceutical Affairs manufacturing Meditoxin using unauthorized and undiluted solution in Korea.
The final ruling is scheduled for early November, but the preliminary ruling is expected to have the same effect as the final ruling, as the ITC usually does not reverse its decision once.
Reporter Park Sang-In si2020@infostock.co.kr
